Services Research Company Careers Support Online Ordering Company Bath ASU is a pharmaceutical specials manufacturer based in Corsham, Wiltshire. Every day our team of specialists produces thousands of life-changing medicines for patients in hospitals across the country. Bath ASU provides a complete range of aseptic manufacturing services including patient-specific chemotherapy, dose banded batch chemotherapy, central intravenous additive service and patient-controlled analgesia products. We are constantly introducing new and innovative methods to improve our services. Our dedicated research and development team explores ways to make our products and services safer, longer-lasting and more dependable. Our purpose-built manufacturing facility and offices were designed for energy efficiency and the energy that we do use is offset by Carbonfund.org to ensure we achieve a zero carbon footprint. 2018 6th September2018 Our parent company, Qualasept Pharmaxo Holdings Limited, is ranked at No. 143 on the 14th annual Sunday Times Grant Thornton Top Track 250. 6th September2018 Our parent company, Qualasept Pharmaxo Holdings Limited, is ranked at No. 63 on the 18th annual Sunday Times Hiscox Tech Track 100. 25 May 2018 Bath ASU tops the South West Business Insider Growth 100 list. 25 May 2018 For the second year running, Bath ASU top the Pharma Fast 50 list. 16 February 2018 Our CEO Chris Watt was ranked one of the top 50 entrepreneurs who have had a positive economic impact in the South West. 2017 11 September 2017 Our parent company, Qualasept Pharmaxo Holdings Limited, is ranked at No. 55 on the 17th annual Sunday Times Hiscox Tech Track 100. 5 September 2017 Bath ASU is included by London Stock Exchange group in their 1000 Companies to Inspire Europe report. 23 January 2017 Corporate finance firm Catalyst have published their inaugural Pharma Fast 50 list of companies, and Bath ASU is number one. 13 January 2017 Bath ASU makes the cover of South West Business Insider magazine. Read the interview with director Chris Watt. 2016 08 September 2016 Our parent company, Qualasept Pharmaxo Holdings Limited, is ranked at No. 60 on the 16th annual Sunday Times Hiscox Tech Track 100. 10 August 2016 Bath ASU is included by London Stock Exchange group in both their “1000 Companies to Inspire Britain” report and their “1000 Companies to Inspire Europe” report. 15 July 2016 Bath ASU is included in Insider Media’s Growth 100 table of the fastest growing companies in the South West. 14 July 2016 Bath ASU one of five finalists in the PwC West Business of the Year Awards 2016. 8 July 2016 Bath ASU’s directors are finalists in the EY Entrepreneur of the Year 2016 awards. 8 June 2016 We celebrated 10 years of being carbon neutral by offsetting our environmental impact with Carbonfund.org. 4 May 2016 Our new, custom-built manufacturing facility at Corsham Science Park officially opens its doors. 2014 26 November 2014 The University of Bath and Bath ASU were awarded funding, under central government’s Knowledge Transfer Programme, for a product development programme relating to the shelf life of intravenous cancer therapies. 2012 2012 Bath ASU develop market leading extended stability data on a range of 17 biological and complex small molecules which help to place it as the largest cytotoxic aseptic “Specials” manufacturer in the UK in terms of customer base and volume. 2011 2011 Bath ASU build new laboratories to enable stability work on biological products and complex small molecules. Our first extended stability on Trastuzumab iv is offered to the market. 2011 Bath ASU offer a patient specific service to hospitals with a range of market leading turnaround times including a 2 hours make and ship. August 2011 Bath ASU is a finalist in PwC West’s Business of the Year awards. 2010 January 2010 Second facility becomes operational on the Corsham site. 2009 May 2009 End third year with over 100 customers and a production of 30,000 units/month. 2008 February 2008 Achieve Edexcel National Learning Centre accreditation and able to award BTEC qualifications for internal and external training. February 2008 Bath ASU export to the EU by providing dose banded chemotherapy products to two hospitals in Copenhagen and a hospital in Aarhus, Denmark. January 2008 Stepped in at 12 hours notice to provide support to the Royal Marsden Hospital after fire and smoke damaged their Chelsea aseptic unit. First products supplied the morning after the fire. 2006 November 2006 First NHS contract won with the supply of dose banded Doxorubicin Syringes to NHS Scotland. 31 October 2006 First products made at our new manufacturing facility in Corsham, Wiltshire. 1 May 2006 Bath ASU becomes a commercial operation via a management buy-out/buy-in from the University of Bath. 2001 2001 Graham Sewell and Richard Plumridge publish: Dose-banding of cytotoxic drugs: A new concept in cancer chemotherapy in the American Journal of Health Systems Pharmacy 2001; 58:1760-4. The article provides the basic framework for implementing the dose banding concept and is a summary of the focus group discussions from August 2000. 2000 2000 Bath ASU begins life at the University of Bath as an education, training and R&D resource for both undergraduate and postgraduates whilst operating as a small commercial aseptic manufacturing facility providing toll manufacturing for Maynepharma and Central Homecare. August 2000 A focus group comprising key pharmacists and nurses was held at the University of Bath. Dose Banding definition was drafted and the key issues debated. Attended by Richard Wastnage who had already implemented dose banding widely when Principal Pharmacist at Singleton Hospital Swansea. June 2000 Bath Aseptic Services Unit founded at the University of Bath by Professor Graham Sewell. Terms & conditions • Privacy policy • Modern slavery statement • Tax strategy • Ethnic minority pay gap report • Gender pay gap report • Press © 2021 Bath ASU